- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04626284
Safety and Effectiveness of NRP for DCD Heart Transplantation (DCDNRPHeart)
Clinical Trial to Evaluate the Safety and Effectiveness of Normothermic Regional Perfusion (NRP) for Resuscitation of Hearts From Donation After Circulatory Death (DCD)
Study Overview
Status
Intervention / Treatment
Detailed Description
The current procedure of DCD organ donation and procurement follows a well-established course for lung, liver, kidney and pancreas transplantation in the United States. DCD transplantation of a heart has been hampered due to concern about the graft viability after the obligatory period of warm ischemia and also the limited ability to assess the graft function after the cessation of circulation. Normothermic regional perfusion restores the circulation and enables in-situ reanimation of thoracic and abdominal organs after the circulatory determination of death. For heart transplantation, the investigators will accept donors between the ages of 18 and 49 without any known history of coronary artery disease, insulin dependent diabetes, or long-term smoking (>20 pack/years) and normal baseline cardiac function (EF>50) assessed with transthoracic echocardiogram. After the authorization for research has been obtained from DCD surrogate, the organs will be allocated through UNOS. When all parties are present and ready, the donor will be withdrawn from life support (i.e., discontinuation of mechanical ventilation and any vasoactive medications). . After circulatory arrest occurs, death is declared by a physician not associated with the transplant teams. Subsequently a period of stand-off is observed (5 minutes for organs donated in Nebraska) to ensure complete cessation of the circulation before organ procurement is commenced. If after withdrawal of life support the patient does not progress to circulatory death within the allotted time, the procurement is abandoned and the patient is transferred out of the operating room and placed on palliative measures.
Given that DCD organ donation is already currently practiced in the US, the same standard approach defined by each state and locality can also be applied to DCD heart donation and will be followed for this protocol at UNMC. However, this protocol will utilize a normothermic regional perfusion (NRP) strategy that involves reestablishment of circulatory blood flow after the period of circulatory arrest has been established and the 5 minutes of standoff time has passed. The local Organ Procurement Organization (LiveOnNE) have reviewed and approved this approach to DCD heart donation. Specifically, normothermic regional perfusion involves the following steps:
- Opening the chest through a standard sternotomy used for heart and lung procurement.
- Ligation of the all the blood vessels that supply blood to the brain to ensure that blood flow to the brain is not reestablished once circulation is restarted as described below.
- Standard cannulation of the aorta and the right atrium as is done for cardiac surgical procedures.
- Initiation of cardiopulmonary bypass, which will re-establish the flow of blood to all organs of the body including the heart under normothermia. The initial step for ligation of the blood vessels to the head is necessary to ensure that blood flow to the brain does not occur.
Once blood flow to the heart is established, the heart will start beating. At 30 minute intervals, the donor will be separated from cardiopulmonary bypass and the heart will be assessed for functionality. If accepted standard DBD procurement will commence. The heart transplantation surgery on the potential recipient will only begin once the heart has been accepted as suitable.
If after assessment the heart is not suitable, cardiopulmonary bypass will be restarted. The donor heart will be reassessed at 30-minute intervals up to 180 minutes. If no significant acceptable recovery occurs and the heart is not deemed suitable for transplantation, then the study will be terminated, but the remaining organs can be recovered as standard practice.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Recipient is ≥ 19 years old
- Recipient, or their designated healthcare proxy, is able and willing to sign informed consent
- Recipient meets standard listing criteria for heart transplantation
Exclusion Criteria:
- Recipient is < 19 years old
- Recipient, or their designated healthcare proxy, is unable to sign informed consent
- Recipient is participating in another interventional trial
- Recipient has a known history of HIV infection
- Recipient has any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Donors After Circulatory Determined death
Recipients receiving an organ from donors after circulatory determined death
|
Heart Transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Utilization rate
Time Frame: Date from the first DCD NRP Heart procurement until the 25th DCD NRP heart procurement, assessed up to 36 months
|
Ratio of successful heart transplants using grafts obtained from DCD donors using NRO to the total number of DCD donors in whom NRP was used to procure an organ
|
Date from the first DCD NRP Heart procurement until the 25th DCD NRP heart procurement, assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft survival
Time Frame: From date of the transplantation to date of death or retransplantation, whichever comes first, assessed up to 12 months
|
Survival of the graft censored either at the time of death of the recipient or retranaplantation
|
From date of the transplantation to date of death or retransplantation, whichever comes first, assessed up to 12 months
|
Primary Graft Dysfunction (PGD)
Time Frame: From day of heart transplantation up to 72 hours post-transplantation
|
Primary Graft Dysfunction as defined by ISHLT
|
From day of heart transplantation up to 72 hours post-transplantation
|
Acute cellular rejection (ACR)
Time Frame: From day of heart transplantation up to 1 year post-transplantation
|
Biopsy proven acute cellular rejection requiring treatment
|
From day of heart transplantation up to 1 year post-transplantation
|
Antibody mediated rejection (AMR)
Time Frame: From day of heart transplantation up to 1 year post-transplantation
|
Biopsy proven antibody mediated rejection
|
From day of heart transplantation up to 1 year post-transplantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marian Urban, MD, PhD, Assistant Professor
Publications and helpful links
General Publications
- Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967 Dec 30;41(48):1271-4. No abstract available.
- Dhital KK, Chew HC, Macdonald PS. Donation after circulatory death heart transplantation. Curr Opin Organ Transplant. 2017 Jun;22(3):189-197. doi: 10.1097/MOT.0000000000000419.
- Messer S, Page A, Colah S, Axell R, Parizkova B, Tsui S, Large S. Human heart transplantation from donation after circulatory-determined death donors using normothermic regional perfusion and cold storage. J Heart Lung Transplant. 2018 Jul;37(7):865-869. doi: 10.1016/j.healun.2018.03.017. Epub 2018 Mar 30.
- Chew HC, Iyer A, Connellan M, Scheuer S, Villanueva J, Gao L, Hicks M, Harkness M, Soto C, Dinale A, Nair P, Watson A, Granger E, Jansz P, Muthiah K, Jabbour A, Kotlyar E, Keogh A, Hayward C, Graham R, Spratt P, Macdonald P, Dhital K. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. J Am Coll Cardiol. 2019 Apr 2;73(12):1447-1459. doi: 10.1016/j.jacc.2018.12.067.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0460-20-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Death
-
University of OxfordRecruitingCause of Mortality | Cause of Neonatal Death | Cause of Child Death | Cause of Maternal Death | Cause of Adult DeathLao People's Democratic Republic, Cambodia, Bangladesh, Myanmar, Thailand
-
Children's Hospital Medical Center, CincinnatiEvery Child Succeeds; de Cavel Family SIDS FoundationCompletedSudden Infant Death Syndrome (SIDS)United States
-
Johns Hopkins UniversityNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingSudden Infant Death | Sudden Unexplained Infant DeathUnited States
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSudden Infant Death SyndromeUnited States
-
Harvard School of Public Health (HSPH)Population Services International; Community Empowerment LabCompletedPerinatal Death | Stillbirth | Neonatal DeathIndia
-
Nantes University HospitalAXA Assurances VIE MutuelleNot yet recruitingSudden Infant Death | Sudden Unexplained Infant DeathFrance
-
Rachel Moon, MDCompletedSudden Infant Death SyndromeUnited States
-
National Center for Research Resources (NCRR)CompletedSudden Infant Death Syndrome
-
CHU de ReimsCompletedSudden Death in ChildrenFrance
-
Lehigh Valley HospitalCompletedPrevention of Sudden DeathUnited States
Clinical Trials on Heart Transplantation
-
Vastra Gotaland RegionRecruiting
-
Cedars-Sinai Medical CenterRecruitingOrgan TransplantUnited States
-
Assistance Publique - Hôpitaux de ParisUniversity Hospital Center of Martinique; Centre Hospitalier Universitaire... and other collaboratorsNot yet recruiting
-
NYU Langone HealthCompletedHeart FailureUnited States
-
Loma Linda UniversityCompletedHeart FailureUnited States
-
Medical University of South CarolinaNot yet recruitingSemilunar Heart Valve Replacement
-
Dr. F. Köhler Chemie GmbHCompletedHeart FailureAustria, Germany
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedLiver Cancer | Hepatobiliary Tract Adenomas and CarcinomasUnited States
-
University Hospital, CaenCompletedAntibiotic Prophylaxis | Adult Heart TransplantationFrance